Shares of Adma Biologics Inc. (NASDAQ:ADMA) rose 7.4% on Friday . The company traded as high as $8.00 and last traded at $7.85, with a volume of 91,890 shares traded. The stock had previously closed at $7.31.

Separately, Maxim Group reduced their target price on shares of Adma Biologics from $24.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, July 25th.

The company’s 50 day moving average is $6.80 and its 200 day moving average is $6.39. The stock’s market cap is $101.16 million.

Adma Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, May 13th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.06. On average, analysts predict that Adma Biologics Inc. will post ($1.38) earnings per share for the current fiscal year.

In other news, Director Jerrold B. Grossman acquired 45,769 shares of the company’s stock in a transaction on Tuesday, May 3rd. The stock was bought at an average cost of $6.50 per share, with a total value of $297,498.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Adam S. Grossman acquired 200,000 shares of the company’s stock in a transaction on Tuesday, May 3rd. The shares were purchased at an average cost of $6.50 per share, with a total value of $1,300,000.00. The disclosure for this purchase can be found here.

ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.